Research into two-party agentic delivery
Supplier updates, policy changes, retesting, acceptance, and rollback.
AAO-112 / Delivery and Operations
Telecom managers should verify that supplier changes reach the operating people, instructions, account tools, and escalation routes affected by them. Technical deployment is incomplete when staff continue to act on obsolete assumptions about what the agent can do.
AAO-094 / Regulation and Compliance
Medical AI service managers should define how operational signals reach the party responsible for assessing safety and performance after deployment. A supplier’s uptime report does not replace a joined evidence route for complaints, changed behavior, human correction, and relevant incidents.
AAO-091 / Regulation and Compliance
Life-sciences executives should require a documented impact assessment when a supplier changes an AI-supported regulated workflow. Prior validation supports the tested use and configuration; it should not be presumed to cover every later model, tool, process, or human-review change.
AAO-082 / Delivery and Operations
Credit and vendor managers should verify that an approved policy change governs the provider’s live workflow from its effective time. Sending a revised document is not evidence that retrieval, instructions, tools, human review, and pending cases apply the new rule correctly.
AAO-079 / Regulation and Compliance
Medical-device service managers should assess provider model updates against the accepted device function, evidence, and applicable change pathway. An upstream improvement is not automatic permission to deploy a changed clinical service.
AAO-074 / Delivery and Operations
Managers should classify provider updates by their effect on the accepted service and require joint reassessment where authority, behavior, evidence, or exposure changes. Routine release labels should not determine whether the buyer must accept a changed operating risk.
AAO-071 / Regulation and Compliance
Healthcare boards should require reassessment when an administrative supplier’s agent begins influencing clinical decisions or patient access. The original procurement label should not determine the governance, evidence, qualifications, or regulatory assessment of the changed function.
AAO-051 / Governance and Accountability
Executives should require a joint decision before a provider change materially alters service authority, behavior, evidence, cost, or dependency. A model or tool update can change the purchased service even when the prime contract remains unchanged.
AAO-045 / Delivery and Operations
Provider executives should define agentic delivery as an ongoing operating service with explicit responsibilities for changes, exceptions, evidence, recovery, and improvement. Platform access and initial implementation do not describe the full obligation.
AAO-047 / Delivery and Operations
Software sourcing managers should accept the released software and its evidence, regardless of how much code agents generated. The supplier must demonstrate secure development, review, testing, provenance, deployment, and support for the actual delivered version.